Profile data is unavailable for this security.
About the company
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. It developed a lead agonist antibody that binds to Dectin-2 and activates human tumor-associated macrophages. It is developing multiple Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
- Revenue in USD (TTM)9.78m
- Net income in USD-65.09m
- Incorporated2015
- Employees100.00
- LocationBolt Biotherapeutics Inc900 Chesapeake DriveREDWOOD CITY 94063United StatesUSA
- Phone+1 (650) 665-9295
- Fax+1 (302) 531-3150
- Websitehttps://boltbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goldenwell Biotech Inc | 940.00 | -137.11k | 19.80m | -- | -- | 5,169.71 | -- | 21,063.83 | -0.0014 | -0.0014 | 0.00001 | 0.00004 | 0.0048 | 0.0031 | -- | -- | -69.82 | -- | -70.29 | -- | 42.55 | -- | -14,586.17 | -- | 21.43 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
| Ibio Inc | 175.00k | -14.36m | 20.01m | 16.00 | -- | 1.07 | -- | 114.35 | -3.97 | -6.65 | 0.0307 | 2.06 | 0.0056 | -- | -- | 10,937.50 | -46.17 | -27.69 | -75.53 | -33.13 | -- | -- | -8,204.57 | -1,862.11 | -- | -- | 0.0736 | -- | -- | -35.52 | 47.31 | -- | -26.66 | -- |
| OpGen Inc | 1.96m | -22.39m | 20.04m | 100.00 | -- | -- | -- | 10.20 | -20.01 | -20.01 | 1.66 | -8.65 | 0.1553 | -- | 6.09 | -- | -176.99 | -87.95 | -15,455.17 | -127.65 | 3.15 | 15.42 | -1,139.66 | -794.78 | -- | -20.25 | -- | -- | 31.11 | 3.02 | 12.38 | -- | 40.20 | -- |
| Spruce Biosciences Inc | 7.10m | -39.43m | 20.24m | 22.00 | -- | 0.3919 | -- | 2.85 | -0.9598 | -0.9598 | 0.1728 | 1.25 | 0.0798 | -- | -- | 244,862.10 | -44.28 | -41.24 | -55.51 | -46.49 | -- | -- | -555.23 | -1,774.39 | -- | -121.12 | 0.0399 | -- | -- | -- | -3.77 | -- | -- | -- |
| Pulmatrix Inc | 10.01m | -9.66m | 20.53m | 22.00 | -- | 1.88 | -- | 2.05 | -2.64 | -2.64 | 2.74 | 2.99 | 0.4145 | -- | 23.16 | 454,772.70 | -40.00 | -46.91 | -44.64 | -58.12 | -- | -- | -96.51 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -27.73m | 20.68m | 8.00 | -- | 1.60 | -- | -- | -4.77 | -4.77 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -114.20 | -95.57 | -159.68 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| Cocrystal Pharma Inc | 0.00 | -18.70m | 20.96m | 12.00 | -- | 1.65 | -- | -- | -1.84 | -1.84 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -76.57 | -50.94 | -83.17 | -52.77 | -- | -- | -- | -1,501.78 | -- | -- | 0.00 | -- | -- | -- | 53.69 | -- | 33.34 | -- |
| Pieris Pharmaceuticals Inc | 1.35m | -15.95m | 21.14m | 46.00 | -- | 1.30 | -- | 15.63 | -12.61 | -12.61 | 1.06 | 12.32 | 0.0338 | -- | 1.91 | 29,391.30 | -39.93 | -28.41 | -68.21 | -39.69 | -- | -- | -1,179.96 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| GlycoMimetics Inc | 10.00k | -39.74m | 21.28m | 35.00 | -- | 1.87 | -- | 2,127.97 | -0.6165 | -0.6165 | 0.0002 | 0.1764 | 0.0003 | -- | 0.0836 | 285.71 | -115.34 | -43.60 | -136.58 | -47.82 | -- | -- | -397,350.50 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Bolt Biotherapeutics Inc | 9.78m | -65.09m | 21.81m | 100.00 | -- | 0.3029 | -- | 2.23 | -1.71 | -1.71 | 0.2567 | 1.88 | 0.0687 | -- | -- | 97,790.00 | -45.72 | -48.32 | -52.52 | -54.03 | -- | -- | -665.56 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Aeon Biopharma Inc | 0.00 | -350.57m | 22.27m | 5.00 | -- | -- | -- | -- | -9.61 | -9.61 | 0.00 | -0.8106 | 0.00 | -- | -- | 0.00 | -3,242.54 | -- | -- | -- | -- | -- | -- | -- | -- | 2.94 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.44m | 22.58m | 4.00 | -- | 8.75 | -- | -- | -1.09 | -1.09 | 0.00 | 0.1589 | 0.00 | -- | -- | 0.00 | -250.15 | -- | -498.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -35.52m | 22.65m | 17.00 | -- | 2.08 | -- | -- | -1.57 | -1.57 | 0.00 | 0.4313 | 0.00 | -- | -- | 0.00 | -122.85 | -57.10 | -195.00 | -71.20 | -- | -- | -- | -- | -- | -- | 0.426 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 22.65m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to Bolt Biotherapeutics Inc's reporting currency: US Dollar USD
20.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 30 Sep 2024 | 3.81m | 9.96% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.07m | 2.79% |
| Stanford Management Co.as of 30 Sep 2024 | 719.55k | 1.88% |
| Adage Capital Management LPas of 30 Sep 2024 | 500.00k | 1.31% |
| Newtyn Management LLCas of 30 Sep 2024 | 468.91k | 1.23% |
| Geode Capital Management LLCas of 30 Sep 2024 | 352.43k | 0.92% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 294.04k | 0.77% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 264.91k | 0.69% |
| Adar1 Capital Management LLCas of 30 Sep 2024 | 244.97k | 0.64% |
| G1 Execution Services LLCas of 30 Sep 2024 | 147.93k | 0.39% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
